Very short blood thinners after stent in older patients
Part of Heart & circulation clinical trials.
This trial tests if a very short course of dual antiplatelet therapy (two blood thinners) after getting a stent is safe and effective for patients aged 65 and older. The goal is to reduce bleeding risks while still preventing heart attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You had a stent placed to open a blocked heart artery, and the procedure went well.
- You agree to take part before leaving the hospital.
- You are not already on blood thinners for conditions like atrial fibrillation.
- You do not have severe kidney disease or a high risk of bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter, lower dose of two blood thinners is safe and effective for patients with a recent heart attack or unstable angina who are at high risk for bleeding. It uses a special stent that might allow for less medication.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
This trial tests if a shorter course of two blood thinners, guided by an ultrasound inside the arteries, is as safe and effective as the standard longer course in people who have had a stent placed for a heart attack or chest pain.
This trial tests if a lower dose of prasugrel, taken alone (without aspirin), is safe and works well for people who have had a stent placed for chest pain or a heart attack. It might be an option for those who need to simplify their medication routine.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
Hear when a new Antiplatelet Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.